Уразаева С.Т., Тогоязова Е.Т., Басыров Т.Б., Нурматалиева Г.Ж., Ташимова Ж.К., Абдылхакова А.А.
ЭПИДЕМИОЛОГИЧЕСКИЕ АСПЕКТЫ ПРИРОДНО-ОЧАГОВЫХ ИНФЕКЦИЙ ЗАПАДНОГО КАЗАХСТАНА.............55

Чумаченко Т.А., Полянченко Ю.И., Макарова В.И.
ЭПИДЕМИОЛОГИЧЕСКИЕ АСПЕКТЫ САЛЬМОНЕЛЕЗА В ХАРЬКОВСКОЙ ОБЛАСТИ В СОВРЕМЕННЫХ УСЛОВИЯХ..................................................61

Шариев А.С., Кадимов Д.С., Жороев А.А., Усубалиева Ж.М.
ОЦЕНКА ДОСТОВЕРНОСТИ ПРИСУТСТВИЯ БОЛЬНЫХ И РЕЗЕРВУАРОВ ВИСЦЕРАЛЬНОГО ЛЕЙШМАНИОЗА В ТРАНСГРАНИЧНЫХ ТЕРРИТОРИЯХ ТАДЖИКИСТАНА И КЫРГЫЗСТАНА .....................................65

Галимов Р.Р., Якупова И.Х., Буранова А.Н., Кутанова Н.Д., Хасанова Г.М., Гумерова Р.З., Старостина В.И.
ЗАБОЛЕВАЕМОСТЬ ОСТРЫМИ КИШЕЧНЫМИ ИНФЕКЦИЯМИ ЗА 2017 ГОД, ПО ДАННЫМ ГБУЗ РБ ИКБ №4...............................................................98

Галымов Н.Г., Садыкова Н.М., Иманова И.А.
ЭССЕНЦИАЛЬНЫЕ МИКРОЭЛЕМЕНТЫ ПРИИНФЕКЦИОННЫХ ЗАБОЛЕВАНИЯХ.............................101

Дамаванова М.Н., Таджiev Б.М., Абдурахманова К.Р.
ПИОДЕРМИЯЛАРДА НЕЙТРОФИЛАРНИНГ ФУНКЦИОНАЛ ФАНОЛЛИГИ.....................................................107

Ибадуллаева Н.С., Жолдасова Е.А., Мусабаев Э.Э., Жолдасова И.Н., Ходжаева М.Э.
ЭКСПРЕССИЯ ЦИРУКУЛЯРИЮЩИХ МИКРОРНК-199a И МИКРОРНК-155 ПРИ ХРОНИЧЕСКИХ ВИРУСНЫХ ГЕПАТИТАХ........................................112

Ибадуллаева Н.С., Жолдасова Е.А., Мусабаев Э.Э., Жолдасова И.Н., Ходжаева М.Э.
ЭКСПРЕССИЯ ЦИРУКУЛЯРИЮЩИХ МИКРОРНК-199a И МИКРОРНК-155 ПРИ ХРОНИЧЕСКИХ ВИРУСНЫХ ГЕПАТИТАХ........................................112

Г.А. Ибадова, Н.Э. Кадирова
КЛИНИЧЕСКИЕ ПРОЯВЛЕНИЯ И ОЦЕНКА ВЗАИМОСВЯЗИ ФЕНОТИПА АЦЕТИЛИРОВАНИЯ С АНТИГЕНСВЯЗЫВАЮЩИМИ ЛИМФОЦИТАМИ К ТКАНЕВЫМ АНТИГЕНАМ У БОЛЬНЫХ С БРУЦЕЛЛЁЗОМ.....................................................115

Изматуллина В.А., Сафарова Л.С., Ибадуллаева Н.С.
ИНДУКЦИЯ РОДОВ У ЖЕНЩИН ПРИ АНТЕНАТАЛЬНОЙ ГИБЕЛИ ПЛОДА С ОТХОЖДЕНИЕМ ОКОЛОПЛОДНЫХ ВОД И ВНУТРИУТРОБНЫМИ ИНФЕКЦИЯМИ.................................................................119

Галимова Р.Р., Якупова И.Х., Буранова А.Н., Кутанова Н.Д., Хасанова Г.М., Гумерова Р.З., Старостина В.И.
ЗАБОЛЕВАЕМОСТЬ ОСТРЫМИ КИШЕЧНЫМИ ИНФЕКЦИЯМИ ЗА 2017 ГОД, ПО ДАННЫМ ГБУЗ РБ ИКБ №4...............................................................98
Despite some improvement in the situation with tuberculosis in Ukraine, it remains difficult and even prognostically unfavorable [10]. In the conditions of the epidemic, the deterioration of the pathomorphosis of tuberculosis, the spread of threatening rates of manifestations of drug resistance of mycobacteria and co-infection of tuberculosis / HIV, an associated pathology worsening the running of tuberculosis is of great importance. Equally important is the relationship between endocrine and immune changes in the running of tuberculosis. According to modern notions, tuberculosis refers to interleukin-dependent immunodeficiency, which is accompanied by pronounced changes in the cytokine network of the body. The role of thyroid hormones in the formation of cellular immunity is well known. Cells of the monocyte-macrophage system are activated by thyroid gland directly and indirectly. Thyroid pathology, in particular autoimmune thyroiditis, is a significant factor in the aggravation of the immune status of patients with tuberculosis. The purpose of this study was to establish the relationship between the thyroid gland and tuberculosis in patients with autoimmune thyroiditis and to assess the effectiveness of sodium selenite treatment in patients with tuberculosis and autoimmune thyroiditis. The results of the study showed that sodium selenite is an effective drug in the treatment of tuberculosis and autoimmune thyroiditis. The results of the study are important for the development of new therapeutic strategies for patients with tuberculosis and autoimmune thyroiditis.

**Key words:** tuberculosis, thyroid, selenium, chemotherapy outcomes.
Objective: to study the effect of sodium selenite on thyroid state and the consequences of chemotherapy in patients with cavitary pulmonary tuberculosis with autoimmune thyroiditis.

Material and methods

The study involved 180 patients with pulmonary tuberculosis and autoimmune thyroiditis aged from 18 to 67 years. The average age of patients was 34.43 years. In the gender perspective, men prevailed - 87%. Observation was carried out in the conditions of the hospital of the regional anti-tuberculosis dispensary № 1 in Kharkov. The research was conducted within the framework of the research theme “Study of mechanisms and determination of markers of favorable and unfavorable running of tuberculosis” (State registration number 0113U002283). Autoimmune pathology of thyroid was confirmed by typical pathological changes of this organ which was established by ultrasound examination on the diagnostic apparatus SSF-240A manufactured by Toshiba Medical Systems. The diffuse pathology of the thyroid gland with heterogeneity of its structure and the heterogeneity of acoustic density with hyperplasia of the gland, hypoplasia or without change in its volume prevailed, which is typical for autoimmune thyroiditis.

The patients were divided into 6 groups: the observation group 1a - patients with drug-sensitive tuberculosis with standardized chemotherapy (SCT) receiving selenium (TB + SCT + Se) and the comparison group 1b - patients with tuberculosis with SCT (TB + SCH) who did not receive selenium; observation group 2a - patients with TB / HIV co-infection with SCT (TB / HIV + SCT + Se) received selenium and comparison group 2b - patients with TB / HIV co-infection with SCT (TB / HIV + SCH); who did not receive selenium; observational group 3a - patients with multidrug-resistant tuberculosis and individual chemotherapy (ICT) including ethinamid (or prothionamid) and PAS. group 3b - multidrug-resistant tuberculosis with the same individual chemotherapy (ICT) including ethinamid (or prothionamid) STDs who did not receive selenium (MRTB + ICT).

Al patients were examined before treatment and after 2 months of chemotherapy in accordance with the standards for monitoring tuberculosis patients during the treatment. Patients in the intensive phase of treatment had standardized chemotherapy, including rifampicin and patients with MRTB - individualized anti-TB chemotherapy, included ethionamide (prothionamide) and PAS/ Co-infection patients also received high-active antiretroviral therapy (HAART) regardless of the level of T-lymphocytes in the blood.

In the complex treatment of patients in the observation group, sodium selenite was included in the form of the drug cefalexin (Cefak, Germany) with 200 micrograms per day per os for 2 months. The comparison groups did not receive the drug selenium.

The levels of selenium (Se) were in the serum of venous blood in all patients before the start of the therapy and after 2 months of therapy in the Synove laboratory on the Perkin Elmer Zeeman AAS 4110 analyzer. Levels of free thyroxine (T4 free), thyroid stimulating hormone (TSH), antibodies to thyroglobulin (a / t TG) and thyroperoxidase (a / t TPO) were measured in the serum of venous blood in all patients before the start of therapy and after 2 months of therapy by the immunoassay ELIZA method.

Biochemical parameters before and after 2 months of therapy were compared between the respective monitoring and control groups. In addition, the rates of treatment effectiveness (%of the stopping of bacterial dynamics) and 8
therapy) and anti-TB chemotherapy in patients with MRTB - individualized anti-TB chemotherapy, included ethionamide (prothionamide) and PAS were compared during the intensive phase of the treatment.

Statistical processing of the data obtained by the method of variation statistics using the standardized package of calculations Microsoft Excel XP. The probability of a divergence of averages was determined by the Student’s t criterion. The critical level of significance (P) in checking statistical hypotheses was assumed to be 0.05.

Results and discussion

In patients with tuberculosis and autoimmune thyroiditis a decreased average serum content of selenium (66.2 ± 8.30) μg / l in group 1a and (66.36 ± 9.93) μg / l in group 1b was noticed in comparison with normal rate (4-130 μg / liter). Low-normal mean free thyroxine value (11.12 ± 0.8) pmol / l in group 1a and (11.21 ± 0.67) in group 1b and increase in TSH level (4.30 ± 1.20) μM / ml in group 1a and (4.00 ± 1.41) μM / ml in group 1b (Table 1) indicate the development of subclinical hypothyroidism in these patients.

Increase of antithyroid antibodies to thyroperoxidase to (42.64 ± 2.7) IU / ml in group 1a and to (38.54 ± 1.27) IU / ml in group 1b and thyroglobulin to (16.88 ± 1.39) IU / ml in group 1a and up to (18.54 ± 1.83) IU / ml in group 1b is a marker of the autoimmune process in the thyroid gland in patients with both subgroups (1a and 1b).

At the end of the intensive phase of chemotherapy,
after a 2-month application of sodium selenite, the average level of selenium is likely to increase to \((95.39 \pm 8.45) \mu g/l\) in group 1a compared with group 1b \((68.50 \pm 5.35) \mu g/l\).

The level of free thyroxine in the group of patients 1a significantly increased to \((13.32 \pm 0.78)\) pmol/l, and an increase in the average level of TSH to \((4.80 \pm 1.52)\) IU/ml compared with baseline levels these hormones. The level of anti-TPO antibodies is believed to decrease as compared with baseline levels \((42.64 \pm 2.72)\) IU/ml to \((43.22 \pm 1.65)\) IU/ml (Table 1).

The level of antibodies to TG also decreases as compared with the starting level of \((16.88 \pm 1.39)\) IU/ml to \((16.88 \pm 1.39)\) IU/ml, and when compared with the comparison group in which the level Antibodies to thyroglobulin increase in the process of chemotherapy with \((31.12 \pm 2.12)\) IU/ml to \((38.54 \pm 1.27)\) IU/ml (Table 1). The results indicate the restoration of the function of the thyroid gland under the influence of selenium in patients with tuberculosis, as well as the treat effect of this trace element in the process of chemotherapy in the thyroid gland.

Autoimmune changes in the thyroid gland in co-infection with TB / HIV are accompanied by selenium deficiency \((63.27 \pm 10.79) \mu g/l\) (group 2a) and \((64.01 \pm 9.43) \mu g/l\) (group 2b). The prescription of sodium selenite restores selenium to normal \((94.69 \mu g/l)\). This group of patients also has a decrease in its hormonal activity, as evidenced by the average low-normal value of the level of free thyroxine \((9.89 \mu g/l)\) and a fairly high level of TTG \((3.43 \mu g/l)\). In the comparison group (group 2b), chemotherapy in the intensive phase leads to an increase in the average level of TSH from \((3.43 \pm 4.12)\) IU/ml, which indicates a weakening of the thyroid status of a patient with co-infection with tuberculosis / HIV under the influence of anti-TB drugs. The application of sodium selenite in the observation group of patients with co-infection leads to a significant increase in the mean free thyroxine level within the normal range \((12.97 \mu g/l)\) and a decrease in TSH level to normal \((1.87 \mu M/ml)\), which optimizes the functional state thyroid gland without the use of thyroid hormones. In the group of co-infected patients receiving sodium selenite, there is also a significant decrease in the average level of antibodies to thyroperoxidase as compared to the baseline \((31.12 \pm 2.12)\) IU/ml and in comparison with the comparison group \((6.77 \mu g/l)\).

### Table 1

<table>
<thead>
<tr>
<th>Groups</th>
<th>TSH (IU/ml)</th>
<th>TTG (IU/ml)</th>
<th>Anti-TPO (IU/ml)</th>
<th>Anti-TG (IU/ml)</th>
<th>Se (μg/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1aTB-AIT-Se (n=30)</td>
<td>8.3(6.9)</td>
<td>37.1(26.8)</td>
<td>8.3(6.9)</td>
<td>15.7(10.6)</td>
<td>95.39(8.45)</td>
</tr>
<tr>
<td>1bTB-AIT-Se (n=30)</td>
<td>8.3(6.9)</td>
<td>37.1(26.8)</td>
<td>8.3(6.9)</td>
<td>15.7(10.6)</td>
<td>68.50(5.35)</td>
</tr>
<tr>
<td>2aTB/HIV-AIT-Se (n=30)</td>
<td>8.3(6.9)</td>
<td>37.1(26.8)</td>
<td>8.3(6.9)</td>
<td>15.7(10.6)</td>
<td>94.69 (μg/l)</td>
</tr>
<tr>
<td>2bTB/HIV-AIT-Se (n=30)</td>
<td>8.3(6.9)</td>
<td>37.1(26.8)</td>
<td>8.3(6.9)</td>
<td>15.7(10.6)</td>
<td>64.01 (μg/l)</td>
</tr>
</tbody>
</table>

Note 1: 1 - data before treatment; 2 - after 60 days of therapy.
Note 2: * The probable difference between the parameters within the group in the treatment \((p \leq 0.05)\). ** Likely difference between the indicators of observation and comparison groups \((p \leq 0.05)\).

### Table 2

<table>
<thead>
<tr>
<th>Parameters</th>
<th>TB-AIT-Se (n=30)</th>
<th>TB-AIT-Se (n=30)</th>
<th>TB-HIV-AIT-Se (n=30)</th>
<th>TB-HIV-AIT-Se (n=30)</th>
<th>MRITB-AIT-Se (n=30)</th>
<th>MRITB-AIT-Se (n=30)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abs. (%)</td>
<td>Abs. (%)</td>
<td>Abs. (%)</td>
<td>Abs. (%)</td>
<td>Abs. (%)</td>
<td>Abs. (%)</td>
<td>Abs. (%)</td>
</tr>
<tr>
<td>Sputum of bacilli excretion</td>
<td>24 (40)</td>
<td>26 (46.6)</td>
<td>20 (66.6)</td>
<td>14 (46.6)</td>
<td>15 (50.0)</td>
<td>17 (56.6)</td>
</tr>
<tr>
<td>Cavities healing</td>
<td>15 (50)</td>
<td>11 (40.0)</td>
<td>15 (43.3)</td>
<td>10 (33.3)</td>
<td>10 (33.3)</td>
<td>7 (23.3)</td>
</tr>
</tbody>
</table>
In the group of patients with multidrug-resistant tuberculosis and with pathological changes of the thyroid gland, the lowest average selenium level is observed in comparison with other groups (56.66 μg / l) (group 3a) before treatment commences. In the same group, there is a low-normal mean free thyroxine level (10.22 pmol / l) with normal values of TSH (1.08 IU / ml). In the comparison group (group 3b), on the background of intensive chemotherapy, a decrease in the mean free thyroxin level to a low anomalous value (from 10.71 to 8.33 pmol / l) was recorded.

The application of sodium selenite in the observation group 3a, restoring the normal content of selenium in the blood to 107.0 μg / l, not only prevents further reduction of free thyroxine, as in the comparison group 3b, but also causes its significant increase within normal physiological values (14, 34 pmol / liter).

The results of the study show the damaging effect of tuberculous infection on the thyroid gland and the presence of subclinical hypothyroidism in patients with tuberculosis with structural thyroid disorders. The obtained data confirm the ability of anti-TB drugs to reduce the function of the thyroid gland, as noted by numerous studies.

Sodium selenite, compensating for the deficiency of selenium in the body of patients with tuberculosis and autoimmune thyroiditis, restores the function of the thyroid gland in the observation groups (groups 1a, 2a and 3a), while in the comparison groups (groups 1b, 2b and 3b) in the process phase of intensive chemotherapy there is a further weakening of the thyroid function. The results of the study also confirm the ability of selenium to lower the titer of antibodies to thyroperoxidase, as reflected in a number of publications [14,19,24].

Thus, selenium sodium provides a ready and stimulating effect on the thyroid gland of patients with tuberculosis with autoimmune thyroiditis and subclinical hypothyroidism or pathological euthyroid syndrome and may be recommended as a therapy for the maintenance of chemotherapy in these individuals.

In evaluating the effect of selenium on the results of chemotherapy of patients with tuberculosis until the end of the intensive care phase, it was found that in 1a, the bacterial excretion stopped in 24% of patients, which is 6.66% more than in the comparison group. In the same group, the rate of healing of caverns is 10% higher when compared with the control group (group 1b) (Table 2).

In the group of TB / HIV co-infected patients receiving selenium (group 2a), stopping of bacilli excretion to the end of the intensive care phase occurred in 20 cases (66.66%), in the comparison group - in 14 cases (46.66%) (group 2 b). The destruction of destructions in this group came in 13 (43.33%) - by 10% more compared with the comparison group - 10 cases (33.33%). In patients with multi-resistant tuberculosis with pathology of the thyroid gland receiving sodium selenite, stopping of bacilli excretion to the end of the intensive care phase occurred in 15 cases (50.0%) and the destruction of lesions - in 10 cases (33.33%). The corresponding indicators in the comparison group were 17 cases (56.66%) 7 cases (23.33%).

The obtained results reflect the positive effect of selenium on the results of chemotherapy, increasing the termination of bacterial release by 6.66% - 20% and healing destruction by 10% when compared with control. The obtained data confirm the results of studies by other authors on the positive effects of selenium on the effects of TB treatment [15].

Conclusions

1. In patients with tuberculosis and AIT in a drug-susceptible process and co-infection with tuberculosis / HIV, subclinical hypothyroidism is observed, and in the case of multi-resistant tuberculosis, a pathological euthyroid syndrome.

2. Anti-tuberculous chemotherapy, which includes rifampicin, thioamides and PAS in patients with tuberculosis and AIT leads to further deepening of hypothyroidism.

3. Inclusion in the complex therapy of various groups of patients with tuberculosis in combination with AIT of sodium selenite leads to the restoration of the function of the thyroid gland and provides a total effect in relation to thyrotropic action of anti-TB chemotherapeutic agents.

4. The appointment of sodium selenite in the intensive phase of treatment of patients with tuberculosis in combination with AIT improves the results of chemotherapy, which leads to an increase in stopping of bacilli excretion by 6.66% -20% and healing destruction by 10% when compared with control.

5. Sodium selenite may be recommended as asatellite therapy when performing chemotherapy of a patient with tuberculosis and AIT in combination with subclinical hypothyroidism and pathological euthyroid syndrome.

REFERENCES:


5. Matveyeva S.L. The effect of selenide deficiency compensation on the effectiveness of treatment of chemoreceptor tuberculosis in patients with thyroid pathol-

Поступила 12.03. 2019